Abstract: A computerized method for monitoring, analyzing, normalizing, applying, predicting, etc., various conditions. The method may comprise receiving data from a source over a channel, generating a report based on the data. The report may contain information associated with one or more events assembled in a standardized format responsive to determining the report corresponds to a first existing incident. The method may include supplementing an existing incident with the information of the report, the existing incident being one of a plurality of existing incidents stored in a database and including information corresponding to one or more events at a specified location and a specified time. The method may also include generating a location-score at a specified location and/or a safety-score for an individual, object, and/or asset at the specified location.

Abstract: A computerized method for monitoring, analyzing, normalizing, applying, predicting, etc., various conditions. The method may comprise receiving data from a source over a channel, generating a report based on the data. The report may contain information associated with one or more events assembled in a standardized format responsive to determining the report corresponds to a first existing incident. The method may include supplementing an existing incident with the information of the report, the existing incident being one of a plurality of existing incidents stored in a database and including information corresponding to one or more events at a specified location and a specified time. The method may also include generating a location-score at a specified location and/or a safety-score for an individual, object, and/or asset at the specified location.

Abstract: Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.

Abstract: Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.

Abstract: A moving image encoding and decoding system reduces compressed moving picture data amounts by producing a prediction signal suitable for moving pictures including dynamic textures. The system includes a moving picture encoding device 1 that includes a block divider 102 receiving a target pixel signal, a prediction signal generator 103 producing a prediction signal, a subtractor 105 producing a differential signal, and a transformer 106 and quantizer 107 producing an encoded differential signal. The encoding device 1 also includes an inverse quantizer 108 and inverse transformer 109 producing a decoded differential signal, an adder 110 producing a reproduction signal, a frame memory 104 storing the reproduction signal as a reference image, and a reference image generator 113. The reference image generator 113 may obtain an observation matrix C by using a pre-existing reference image.

Abstract: The patent application relates to new heterocyclic compounds of the general formula (I), in which R, R1, R2, Q, T, n and p have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors.

Abstract: Heterocyclic compounds of the general formula (I) are provided in which R, R1, R2, R3, R4 and n have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldostereone synthase inhibitors,

Abstract: The application relates to novel substituted piperidines of the general formula (II) in which R1?, R2?, R2?, R4?, X, Z, m and n have the meanings defined in the description, to a process for the preparation thereof and to the use of these compounds as medicines, especially as renin inhibitors.

Abstract: Heterocyclic compounds of the formula (I) and salts, preferably pharmaceutically acceptable salts thereof, are provided in which R, R1, R2, Q, m and n have the meanings explained in detail in the description. Also provided are a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.

Abstract: Novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof, in which R, R1, R1?, Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.

Abstract: The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferable pharmaceutically acceptable salts, thereof, in which R, R1, R2, R3, Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.

Abstract: The patent application relates to new heterocyclic compounds of the general formula (I) in which R, R1, R2, W, X, Y, Z and n have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors.

Abstract: Compounds of the general formula (I) or its salt or a compound in which one or more atoms are replaced by their stable, nonradio-active isotopes, in particular its pharmaceutically acceptable salt; in which X is —CH2—; R is a mono- to tetra-substituted, mono- or bicyclic, unsaturated heterocyclic radical having 1 to 4 nitrogen atoms, R2 is C1-6alkyl or C3-6cycloalkyl; R3 is independently of one another H, C1-6alkyl, C1-6alkoxycarbonyl or C1-6alkanoyl; R4 is C2-6alkenyl, C1-6alkyl, unsubstituted or substituted aryl-C1-6alkyl or C3-8cycloalkyl; R5 is -Lm-R6; L is C1-6alkylene which is optionally substituted by 1-4 halogen, or a linker: formula (II) n=0, 1 or 2; m=0 or 1; R6 is a radical composed of 2 cyclic systems selected from bicyclo[x.y.z]alkyl, spiro[o.p]alkyl, mono- or bioxabicyclo[x.y.z]alkyl or mono- or bioxaspiro[o.

Abstract: The patent application relates to new heterocyclic compounds of the general formula (I) in which A, R, R1, R2, U, V, W, X, Y, Z, n and p have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors.

Abstract: Compounds of the general formula (formula I) in which the meanings of the substituents R1 to R6 are as indicated in claim 1, have renin-inhibiting properties and can be used as medicines.

Abstract: A moving image encoding and decoding system reduces compressed moving picture data amounts by producing a prediction signal suitable for moving pictures including dynamic textures. The system includes a moving picture encoding device 1 that includes a block divider 102 receiving a target pixel signal, a prediction signal generator 103 producing a prediction signal, a subtractor 105 producing a differential signal, and a transformer 106 and quantizer 107 producing an encoded differential signal. The encoding device 1 also includes an inverse quantizer 108 and inverse transformer 109 producing a decoded differential signal, an adder 110 producing a reproduction signal, a frame memory 104 storing the reproduction signal as a reference image, and a reference image generator 113. The reference image generator 113 may obtain an observation matrix C by using a pre-existing reference image.

Abstract: The patent application relates to new heterocyclic compounds of the general formula (I) in which R, R1, R2, R3, R4 and n have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldosterone synthase inhibitors.

Abstract: Compounds of the general formula (formula I) in which the meanings of the substituents R1 and R6 are as indicated in claim 1, have renin-inhibiting properties and can be used as medicines.

Abstract: Heterocyclic compounds of the formula (I) and salts, preferably pharmaceutically acceptable salts thereof, are provided in which R, R1, R2, Q, m and n have the meanings explained in detail in the description. Also provided are a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.

Abstract: Heterocyclic compounds of the general formula (I) are provided in which R, R1, R2, R3, R4 and n have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these compounds as medicaments, particularly as aldostereone synthase inhibitors,